Inositol can effectively and safely manage polycystic ovary syndrome

Published On: 22 Apr, 2023 1:07 PM | Updated On: 20 May, 2024 10:18 AM

Inositol can effectively and safely manage polycystic ovary syndrome

Metformin is considered the gold standard insulin sensitizer and is popularly used to treat insulin resistance in polycystic ovary syndrome (PCOS), yet it may cause gastrointestinal adverse effects.

Inositols may serve as a potential alternative to metformin in treating PCOS. Hence, the current systematic review evaluated inositols' efficacy as well as safety in managing PCOS.

It sorted randomized controlled trials (RCTs) that contained women diagnosed with PCOS and contrasted any inositols treatment with metformin or placebo. The study looked for cycle normalization, body mass index (BMI), parameters of carbohydrate metabolism, and clinical and laboratory hyperandrogenism. 

It observed-


  • Inclusion of twenty-six RCTs that comprised data from 1691 patients (806 inositols, 311 placebo, and 509 metformin groups). 
  • Patients treated with inositols had 1.79 higher chances of having a regular menstrual cycle than the placebo.
  • Inositols were non-inferior to metformin in this outcome. 
  • Insulin inositol treatment induced a greater decrease in BMI, free testosterone, total testosterone, androstenedione, glucose levels, and AUC than the placebo. 
  • Inositol remarkably increased sex-hormone-binding globulin than placebo.

This study proves Inositol is an effective and safe treatment for PCOS, which is non-inferior in most outcomes compared to metformin, the gold standard treatment.

Greff D, Juhász AE, Váncsa S. et al. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol. 2023;21. https://doi.org/10.1186/s12958-023-01055-z

user
IJCP Editorial Team

Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.

 More FAQs by IJCP Editorial Team
Logo

Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks